Such combined efficacy (achieving clinical cure and microbiologic cure) of Zaynich is highest ever among all the FDA-approved novel antibiotics developed in the last more than 10 years
Lisdexamfetamine Dimesylate is indicated for the treatment of Attention Deficit Hyperactivity Disorder in adults and pediatric patients aged six years and older
The group reported Q3FY25 operating revenue of Rs 3,821 crore, driven by sustained double-digit growth of 14 per cent in biosimilars
Biocon’s subsidiary Biocon Biologics Limited, which also participated independently in the assessment for the first time, reported an S&P Global ESG Score of 53
Based on DESTINY-Breast06 Phase III trial results which showed Enhertu demonstrated superiority vs. chemotherapy with a median progression-free survival of more than one year
OneSource operates five cGMP facilities and has a strong track record, with 138 successful regulatory and customer audits to date by all major regulatory bodies
The 33% year-over-year revenue growth and a remarkable 45% surge in gross profit reflect our strong market presence and efficient execution across therapeutic segments
RPG Life Sciences has reported total income of Rs. 176.02 crore during the period ended December 31, 2024
BRAFTOVI combination regimen is the first and only targeted therapy approvedby the U.S. FDA for treatment-naïve patients with metastatic colorectal cancer with a BRAF V600E mutation
Q3 FY25 revenue up 24% to Rs 3,230 crore
Subscribe To Our Newsletter & Stay Updated
